Novel medications for asthma: A look at the future

Expert Opinion on Investigational Drugs

Volumn 16, Issue 6, 2007, Pages 889-897

  Rubin, Bruce K ^a   Fink, James B ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NEKTAR THERAPEUTICS   (United States)

Author keywords

Airway remodeling; Bronchodilators; Corticosteroids; Cytokines; Inflammation; Mucus

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CARMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CILOMILAST; CLARITHROMYCIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DATURA STRAMONIUM EXTRACT; FLUTICASONE; FORMOTEROL; GW 642444M; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE INHIBITOR; INDACATEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MEPOLIZUMAB; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL; SIMVASTATIN; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AEROSOL; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRY POWDER; ENVIRONMENTAL PROTECTION; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; METERED DOSE INHALER; MUCUS SECRETION; NAUSEA AND VOMITING; NONHUMAN; PATIENT SAFETY; RESPIRATORY AIRFLOW; REVIEW; TACHYCARDIA;

AIRWAY OBSTRUCTION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; MUCUS; NEUTROPHILS; PHARMACOGENETICS;

EID: 34250016279     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.6.889     Document Type: Review

References (66)

1. CORRY DB, IRVIN CG: Promise and pitfalls in animal-based asthma research: building a better mousetrap. Immunol. Res. (2006) 35:279-294.
2. LEACH CL: The CFC to HFA transition and its impact on pulmonary drug development. Respir. Care (2005) 50:1201-1208.
3. LEACH CL, DAVIDSON PJ, HASSELQUIST BE, BOUDREAU RJ: Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest (2002) 122:510-516.
4. RUBIN BK, FINK JB: Treatment delivery systems. In: Clinical Asthma (Chapter 34), Castro M, Kraft M (Eds), Elsevier (2007) (In Press).
5. ALVAREZ GG, SCHULZER M, JUNG D, FITZGERALD JM: A systematic review of risk factors associated with near-fatal and fatal asthma. Can. Respir. J. (2005) 12:265-270.
6. MARTINEZ FD: Serious adverse events and death associated with treatment using long-acting β-agonists. Clin. Rev. Allergy Immunol. (2006) 31:269-278.
7. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. (2001) 124:183-186.
8. 2-adrenergic receptor genotype in subjects with persistent asthma. J. Allergy Clin. Immunol. (2006) 118:809-816.
9. GLASSROTH J: The role of long-acting β agonists in the management of asthma: analysis, meta-analysis, and more analysis. Ann. Int. Med. (2006) 144:936-937.
10. LOTVALL J, PALMQVIST M, ARVIDSSON P, MALONEY A, VENTRESCA GP, WARD J: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterot in asthmatic patients. J. Allergy Clin. Immunol. (2001) 108:726-731.
11. Levalbuterol for asthma. Med. Lett. (1999) 41:51-53.
12. 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2005) 14(7):775-783.
13. CURRIE GP: Indacaterol (Novartis/SkyePharma). Curr. Opin. Investig. Drugs (2006) 7:457-463.
14. BARNES PJ: Theophylline: new perspectives for an old drug. Am. J. Respir. Crit. Care Med. (2003) 167:813-818.
15. BOSWELL-SMITH V, PAGE CP: Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert Opin. Investig. Drugs (2006) 15(9):1105-1113.
16. MATA M, SARRIA B, BUENESTADO A, CORTIJO J, CERDA M, MORCILLO EJ: Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax (2005) 60:144-152.
17. LIPWORTH BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 365:167-175.
18. CHUNG KF: Phosphodiesterase inhibitors in airways disease. Eur J. Pharmacol. (2006) 533:110-117.
19. KROEGEL C, FOERSTER M: Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. Expert Opin. Investig. Drugs (2007) 16(1):109-124.
20. 1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyll-8-benzyl-7- {2-ethyl-(2-hydroxy-ethyl)-amino]-ethyll-l- propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J. Pharmacol, Exp. Ther. (2005) 315:329-336.
21. DESSANGES JF: A history of nebulization. J. Aerosol Med. (2001) 14:65-71.
22. WESTBY M, BENSON M, GIBSON P: Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst. Rev. (2004) 3:CD003269.
23. COLICE GL: The newly developed inhaled corticosteroid cidesonide for the treatment of asthma. Expert Opin. Pharmacother. (2006) 7(15):2107-2117.
24. BELVISI MG, HELE DJ: Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm. Pharmacol. Ther. (2003) 16:321-325.
25. CURRIE GP, MCLAUGHLIN K: The expanding role of leukotriene receptor antagonists in chronic asthma. Ann. Allergy Asthma Immunol. (2006) 97:731-741.
26. CORRY DB, KHERADMAND F: Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma. Am. J. Respir Med. (2002) 1:185-193.
27. STRUNK RC, BLOOMBERG GR: Omalizumab for asthma. N. Engl. J. Med. (2006) 354:2689-2695.
28. KASAIAN MT, DONALDSON DD, TCHISTLAKOVA L et al: Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am. J. Resp. Cell Molec. Biol. (2007) 36(3):368-376.
29. BIRRELL MA, HARDAKER E, WONG S et al: Iκ-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am. J. Respir. Crit. Care Med. (2005) 172:962-971.
30. CHOI IW, KIM DK, KO HM, LEE HK: Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-κB inhibits established asthmatic reaction in mice. Int. Immunopharmacol. (2004) 4:1817-1828.
31. STASSEN M, KLEIN M, BECKER M et al: p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1. Mol. Immunol. (2007) 44:926-933.
32. DUAN W, CHAN JH, MCKAY K et al: Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. (2005) 171:571-578.
33. NEWTON R, HOLDEN N: Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? BioDrugs (2003) 17:113-129.
34. BEEH KM, BEIER J, MEYER M, BUHL R, ZAHLTEN R, WOLFF G: Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm. Pharmacol. Ther. (2006) 19:233-241.
35. ROMANO SJ: Selectin antagonists: therapeutic potential in asthma and COPD. Treat. Respir. Med. (2005) 4:85-94.
36. MATSUBARA S, LI G, TAKEDA K et al: Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. (2006) 173:56-63.
37. VANDERSLICE P, BIEDIGER RJ, WOODSIDE DG, BERENS KL, HOLLAND GW, DIXON RA: Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Pulm. Pharmacol. Ther. (2004) 17:1-10.
38. EL MIEDANY Y, YOUSSEF S, AHMED I, EL GAAFARY M: Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. (2006) 97:105-109.
39. WEGMANN M, GOGGEL R, SEL S et al: Effect of a low molecular weight CCR-3 antagonist on chronic experimental asthma. Am. J. Respir. Cell Mol. Biol. (2007) 36:61-67.
40. FRYER AD, STEIN LH, NIE Z et al: Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J. Clin. Invest. (2006) 116:228-236.
41. 3 receptor antagonist, SR 142801, in a murine model of asthma. Eur J. Pharmacol. (2001) 421:201-205.
42. CORRIGAN CJ: Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am. J. Respir. Med. (2002) 1:47-54.
43. ZHANG X, MOILANEN E, KANKAANRANTA H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J. Pharmacol. (2001) 431:365-371.
44. MCKAY A, LEUNG BP, MCINNES IB, THOMSON NC, LIEW FY: A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J. Immunol. (2004) 172:2903-2908.
45. ITKIN IH, MENZEL ML: The use of macrolide antibiotic substances in the treatment of asthma. J. Allergy (1970) 45:146-162.
46. SHINKAI M, FOSTER G, RUBIN BK: Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am. J. Physiol. Lung Cell Molec. Physiol. (2006) 290:L75-L85.
47. RUBIN BK, HENKE MO: Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest (2004) 125:70S-78S.
48. FONSECA-ATEN M, OKADA PJ, BOWLWARE KL et al: Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. Ann. Allergy Asthma Immunol. (2006) 97:457-463.
49. BERRY MA, HARGADON B, SHELLEY M et al: Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med. (2006) 354:697-708.
50. ERIN EM, LEAKER BR, NICHOLSON GC et al: The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am. J. Respir. Crit. Care Med. (2006) 174:753-762.
51. ADAMZIK M, GROEBEN H, FARAHANI R, LEHMANN N, PETERS J: Intravenous lidocaine after tracheal intubation mitigates bronchoconstriction in patients with asthma. Anesth. Analg. (2007) 104:168-172.
52. HUNT LW, FRIGAS E, BUTTERFIELD JH et al: Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. J. Allergy Clin. Immunol. (2004) 113:853-839.
53. OH CK: Mast cell mediators in airway remodeling. Chem. Immunol. Allergy (2005) 87:85-100.
54. DEMEDTS IK, BRUSSELLE GG, BRACKE KR, VERMAELEN KY, PAUWELS RA: Matrix metalloproteinases in asthma and COPD. Curr. Opin. Pharmacol. (2005) 5:257-263.
55. CHO JY, MILLER M, MCELWAIN K et al: Remodeling associated expression of matrix metalloproteinase 9 but not tissue inhibitor of metalloproteinase 1 in airway epithelium: modulation by immunostimulatory DNA. J. Allergy Clin. Immunol. (2006) 117:618-625.
56. OHBAYASHI H, SHIMOKATA K: Matrix metalloproteinase-9 and airway remodeling in asthma. Curr. Drug Targets Inflamm. Allergy (2005) 4:177-181.
57. 2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in the ferret trachea. Am. J. Physiol. Lung Cell Molec. Physiol. (2007) 292:L62-L67.
58. RUBIN BK, TOMKIEWICZ R, FAHYJV, GREEN FY. Histopathology of fatal asthma. Drowing in mucus. Pedes Pulmonol. (2001) 23:88S-89S.
59. 2. Am. J. Physiol. (1998) 275:L740-L747.
60. ERPENBECK VJ, HAGENBERG A, DULKYS Y et al: Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. Am. J. Respir. Crit. Care Med. (2004) 169:578-586.
61. HOLGATE ST, YANG Y, HAITCHI HM et al: The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc. Am. Thorac. Soc. (2006) 3:440-443.
62. HOLGATE ST, HOLLOWAY J, WILSON S et al.: Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J. Allergy Clin. Immunol. (2006) 117:496-506.
63. RUBIN BK: What does it mean when a patient says, 'my asthma medication is not working?' Chest (2004) 126:972-981.
64. CANONICA GW, CASTELLANI P, CAZZOLA M et al; THE CAST (CONTROL OF ASTHMA BY SYMBICORT TURBUHALER) STUDY GROUP: Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm. Pharmacol. Ther. (2004) 17:239-247.
65. MOORE WC, PETERS SP: Severe asthma: an overview. J. Allergy Clin. Immunol. (2006) 117:487-494.
66. BARNES PJ: New therapies for asthma. Trends Mol. Med. (2006) 12:515-520.